Diffuse intrinsic pontine glioma remains one of the most fatal pediatric central nervous system malignancies. Conventional chemotherapy frequently fails because the blood-brain barrier restricts drug penetration into the brainstem. Consequently, clinicians require innovative therapeutic strategies to bypass systemic barriers and deliver concentrated anti-tumor agents directly to the neoplasm. A recent phase 1 dose-escalation clinical trial investigated the safety and dosimetric profile of 124I-Omburtamab for DIPG administered via magnetic resonance-guided stereotactic convection-enhanced delivery. This innovative radio-immunotheranostic platform specifically targets the B7-H3 antigen, which shows dense expression on pontine glioma cells. By utilizing the theranostic isotope iodine-124, the investigative team successfully combined real-time positron emission tomography imaging with localized radiation therapy. The landmark study enrolled fifty pediatric patients after completion of standard external-beam radiation therapy. Therefore, this therapeutic approach represents a major technological leap toward achieving precise intralesional therapy in high-risk pediatric brain tumors without inflicting severe systemic toxicities.

Understanding Diffuse Intrinsic Pontine Glioma and CED Mechanisms

Diffuse intrinsic pontine glioma presents unique neurosurgical and oncological challenges due to its infiltrative growth pattern within critical brainstem nuclei. Because surgical resection remains impossible in the pons, external beam radiation therapy has served as the historical standard of care. However, radiation therapy offers only transient disease control, and median overall survival rarely exceeds twelve months from initial diagnosis. Systemic pharmacotherapy has similarly produced disappointing results because the intact blood-brain barrier severely hinders macromolecular transport. To overcome these pharmacological limitations, researchers developed convection-enhanced delivery as a stereotactic micro-infusion technique. Convection-enhanced delivery establishes a continuous positive hydrostatic pressure gradient through surgically placed intracerebral cannulas. Consequently, this direct fluid infusion drives therapeutic macromolecules through the interstitial spaces of the brain tissue. This convective mechanism generates homogeneous drug distribution throughout large tumor volumes without relying solely on passive diffusion. Furthermore, direct intratumoral infusion achieves exceptionally high local concentrations while keeping systemic drug exposure exceptionally low. Thus, stereotactic delivery provides a viable avenue for targeting aggressive brainstem tumors.

Dose Escalation and Theranostic Evaluation of 124I-Omburtamab for DIPG

The phase 1 open-label clinical trial implemented a standard 3+3 dose-escalation schema to determine the safety and maximum tolerated activity of 124I-Omburtamab for DIPG. Omburtamab is a murine monoclonal antibody directed against B7-H3, an immune-checkpoint glycoprotein heavily expressed in pediatric solid tumors. The investigators radiolabeled this monoclonal antibody with iodine-124, an emission isotope that facilitates quantitative positron emission tomography. Following standard external beam radiation, fifty pediatric patients underwent stereotactic catheter placement into the pontine lesion under magnetic resonance guidance. The clinical protocol tested escalating radioactivity levels ranging from 0.25 mCi to 10.0 mCi, alongside infused volume escalations spanning from 0.25 mL to 10.0 mL. Serial positron emission tomography and magnetic resonance imaging performed after administration allowed clinicians to track intralesional distribution in real time. Consequently, the research team directly visualized the spatial-temporal kinetics and antibody clearance over several days post-infusion. This unique theranostic approach confirmed that the radiopharmaceutical achieved widespread intratumoral coverage while remaining largely contained within the target brainstem volume.

Key Safety Profiles and Toxicity Findings

Safety evaluation served as the primary clinical outcome throughout the thirty days following intracranial convection-enhanced delivery. Overall, the stereotactic infusion procedure demonstrated a manageable safety profile across the pediatric cohort. The trial investigators established the maximum tolerated activity protocol level at 6 mCi (222 MBq). During dose escalation, five dose-limiting toxicity events occurred across higher dose cohorts. Additionally, eleven patients experienced treatment-related grade 3 central nervous system toxicities, which clinicians attributed to transient local tissue swelling, volume intolerance, or focal radiation injury. The reported grade 3 neurologic adverse events primarily included motor weakness, dysarthria, ataxia, dysphagia, and gait disturbances. Importantly, investigators observed zero grade 4 or grade 5 treatment-related central nervous system toxicities throughout the entire study period. Most adverse events proved transient and responded promptly to supportive medical interventions, including corticosteroid therapy. Because the radiolabeled antibody remained tightly confined within the brainstem, systemic hematologic toxicities were absent. Consequently, the study confirmed the procedural feasibility and safety of high-volume brainstem micro-infusions.

Survival Outcomes and Radio-Dosimetric Distribution

Beyond safety parameters, the study evaluated secondary outcomes including overall survival and radiation dosimetry metrics. The cohort achieved an encouraging median overall survival of 15.29 months from initial diagnosis, with a 95% confidence interval ranging between 12.20 and 16.83 months. Furthermore, the estimated overall survival rates reached 65.4% at one year, 18.4% at two years, and 11.7% at three years post-diagnosis. These survival metrics compare favorably against historical benchmarks, where two-year survival rates typically remain below ten percent. Quantitative dosimetric analysis demonstrated an overall mean absorbed radiation dose of 35.2 ± 18 cGy per megabecquerel within the pontine lesion. Most remarkably, the lesion-to-whole-body absorbed dose ratio averaged 816 across all administered activity cohorts. This extraordinarily high ratio proves that convection-enhanced delivery concentrates therapeutic radiation within the neoplasm while sparing vital peripheral organs. Therefore, the micro-infusion approach delivers tumoricidal radiation doses directly to infiltrating glioma cells without generating significant whole-body radiation burdens.

Clinical Implications for Pediatric Neuro-Oncology

The findings from this trial carry profound implications for pediatric neuro-oncology and radiopharmaceutical development. First, this investigation represents the first-in-human theranostic application of an iodine-124 radiopharmaceutical acting concurrently as an imaging tracer and therapeutic payload. Second, the study validates stereotactic convection-enhanced delivery as a reproducible technique for navigating delicate brainstem architecture. Because conventional intravenous systemic therapies fail to cross the intact blood-brain barrier, direct delivery techniques offer an indispensable therapeutic framework for childhood brain tumors. In addition, identifying the maximum tolerated activity level provides clear dosing parameters for subsequent phase 2 multi-center efficacy trials. Clinicians can now explore multi-catheter configurations, iterative re-dosing schedules, or combination regimens featuring whole-neuroaxis radiotherapy. Furthermore, the successful targeting of the B7-H3 antigen suggests broader clinical utility for other radioimmunotherapy conjugates across central nervous system malignancies. Thus, this milestone study opens new avenues for aggressive pontine tumors that previously lacked effective therapeutic interventions.

Frequently Asked Questions

What is the primary target of 124I-omburtamab in DIPG?

The monoclonal antibody omburtamab specifically targets B7-H3, an immunomodulatory glycoprotein overexpressed on diffuse intrinsic pontine glioma cells. When conjugated to the positron-emitting isotope iodine-124, it enables precise theranostic tumor binding. This targeted approach delivers localized radiation directly to neoplastic pontine cells while sparing healthy surrounding brain tissue from significant systemic exposure.

How does convection-enhanced delivery bypass the blood-brain barrier?

Convection-enhanced delivery bypasses the blood-brain barrier through the stereotactic placement of micro-cannulas directly into the tumor parenchyma. A positive hydrostatic pressure gradient continuously pumps therapeutic fluids into interstitial brain spaces. This convective bulk flow distributes large macromolecules across substantial tissue volumes without relying on passive vascular transport or systemic absorption mechanisms.

What was the maximum tolerated activity identified in the trial?

The phase 1 dose-escalation clinical trial established the protocol maximum tolerated activity at 6 mCi (222 MBq) for 124I-omburtamab. At this therapeutic level, the drug delivered potent intralesional radiation doses averaging 35.2 cGy per MBq, maintaining a favorable safety profile without causing any grade 4 or grade 5 central nervous system toxicities.

Disclaimer: This content is for informational and educational purposes only. It is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Souweidane MM et al. Phase 1 dose-escalation trial using convection-enhanced delivery of radio-immunotheranostic 124I-Omburtamab for diffuse intrinsic pontine glioma. Neuro Oncol. 2025 Sep 17. doi: 10.1093/neuonc/noaf039. PMID: 39969230.
2. Franca Velo A, Giantini Larsen A, Humm JL, Zanzonico P, Haque S, Souweidane M, Pandit-Taskar N. Determination of the Intralesional Distribution of Theranostic 124I-Omburtamab Convection-Enhanced Delivery in Treatment of Diffuse Intrinsic Pontine Glioma. J Nucl Med. 2025;66(6):886-891. doi: 10.2967/jnumed.124.267995.
3. Souweidane MM, Kramer K, Pandit-Taskar N, et al. Convection-enhanced delivery for diffuse intrinsic pontine glioma: a single-centre, dose-escalation, phase 1 trial. Lancet Oncol. 2018;19(8):1040-1050. doi: 10.1016/S1470-2045(18)30322-X.